469 Treffer:
61.
A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors *Nur für NSCLS offen*
NCT Heidelberg » Ihre Suche
Datum: 2025-10-23
62.
A Phase 1b/2 Open-Label Study of Disitamab Vedotin Monotherapy or in Combination With Other Anticancer Therapies in Solid Tumors
NCT Heidelberg » Ihre Suche
Datum: 2025-10-23
63.
A phase 1 / 2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic Gastrointestinal cancers explOring treatment comBinations with peLarEorep and aTezolizumab
NCT Heidelberg » Ihre Suche
Datum: 2025-10-23
64.
A phase 1 / 2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic Gastrointestinal cancers explOring treatment comBinations with peLarEorep and aTezolizumab
NCT Heidelberg » Ihre Suche
Datum: 2025-10-23
65.
A phase 1 / 2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic Gastrointestinal cancers explOring treatment comBinations with peLarEorep and aTezolizumab
NCT Heidelberg » Ihre Suche
Datum: 2025-10-23
66.
A phase 1 / 2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic Gastrointestinal cancers explOring treatment comBinations with peLarEorep and aTezolizumab
NCT Heidelberg » Ihre Suche
Datum: 2025-10-23
67.
A Phase 1b/2 Open-Label Study of Disitamab Vedotin Monotherapy or in Combination With Other Anticancer Therapies in Solid Tumors
NCT Heidelberg » Ihre Suche
Datum: 2025-10-23